Shift in diagnostic classification of migraine after initiation of preventive treatment with eptinezumab: post hoc analysis of the PROMISE studies
Abstract Background Monthly headache frequency directly correlates with personal/societal burden and impacts severity and preventive treatment decisions. This post hoc analysis identified shifts from higher to lower frequency headache categories over 6 months in patients with migraine participating...
Main Authors: | Patricia Pozo-Rosich, David W. Dodick, Anders Ettrup, Joe Hirman, Roger Cady |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-10-01
|
Series: | BMC Neurology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12883-022-02914-9 |
Similar Items
-
Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies
by: Timothy R. Smith, et al.
Published: (2021-11-01) -
Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF study
by: Roger Cady, et al.
Published: (2022-07-01) -
Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study
by: Stephen Silberstein, et al.
Published: (2020-10-01) -
Measuring dose-related efficacy of eptinezumab for migraine prevention: post hoc analysis of PROMISE-1 and PROMISE-2
by: Rami Apelian, et al.
Published: (2022-04-01) -
Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab
by: Andrew Blumenfeld, et al.
Published: (2022-07-01)